Goldman Sachs Group Inc Abeona Therapeutics Inc. Transaction History

Goldman Sachs Group Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$4.07 - $8.68 $698,139 - $1.49 Million	171,533 New	171,533 $1.24 Million
Q2 2023 May 14, 2024	BUY	$2.76 - $5.27 $138,022 - $263,542	50,008 Added 30.63%	213,282 $859,000
Q2 2023 Aug 14, 2023	BUY	$2.76 - $5.27 $138,022 - $263,542	50,008 Added 30.63%	213,282 $859,000
Q1 2023 May 14, 2024	SELL	$2.25 - $3.27 $14,370 - $20,885	-6,387 Reduced 3.76%	163,274 $460,000
Q1 2023 May 11, 2023	SELL	$2.25 - $3.27 $14,370 - $20,885	-6,387 Reduced 3.76%	163,274 $460,000
Q4 2022 May 14, 2024	BUY	$2.4 - $5.65 $407,186 - $958,584	169,661 New	169,661 $522,000
Q4 2022 Feb 13, 2023	BUY	$2.4 - $5.65 $407,186 - $958,584	169,661 New	169,661 $522,000

26.9M

614K

45K

Ticker ABEO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 5,950,380
Market Cap $33.9M
Description
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-a...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.